The concurrent administration of live vaccines with Remicade is not recommended.Fatal outcome due to disseminated BCG infection has been reported in an infant who received a BCG vaccine after Other uses of therapeutic infectious agents such as live attenuated bacteria (e.g., BCG bladder instillation for the treatment of cancer) could result in clinical infections, including disseminated infections.
The infusion solution should be prepared and administered by a trained medical professional using aseptic technique by the following procedure:No physical biochemical compatibility studies have been conducted to evaluate the co-administration of Remicade with other agents. Patients received either placebo+MTX or one of 4 doses/schedules of Remicade+MTX: 3 mg/kg or 10 mg/kg of Remicade by IV infusion at Weeks 0, 2 and 6 followed by additional infusions every 4 or 8 weeks in combination with MTX.Study RA II was a placebo-controlled study of 3 active treatment arms in 1004 MTX naive patients of 3 or fewer years' duration active RA. Patients randomized to Remicade maintenance had a longer time to loss of fistula response compared to the placebo maintenance group (Figure 2). Chemotherapy administration, intravenous infusion technique, each additional hour, single or initial substance (list separately in addition to code 96413 for initial hour of infusion services) Periodic screening should continue in women treated with Remicade In the controlled portions of clinical trials of some TNF blockers including Remicade, more malignancies (excluding lymphoma and nonmelanoma skin cancer [NMSC]) have been observed in patients receiving those TNF blockers compared with control patients. Abstract P626.48. 62. Concomitant stable doses of aminosalicylates, corticosteroids and/or immunomodulatory agents were permitted and 92% of patients continued to receive at least one of these medications.In the single-dose trial of 108 adult patients, 16% (4/25) of placebo patients achieved a clinical response (decrease in CDAI ≥70 points) at Week 4 vs. 81% (22/27) of patients receiving 5 mg/kg Remicade (p<0.001, two-sided, Fisher's Exact test). Dewint P, Hansen BE, Verhey E, et al.
Accordingly, the information may not be correct or comprehensive.
Thalidomide therapy for patients with refractory Crohn’s disease: an open-label trial.
Patients with moderate or severe heart failure taking REMICADE At baseline, the median Mayo score was 8, 53% of patients were receiving immunomodulator therapy (6-MP/AZA/MTX), and 62% of patients were receiving corticosteroids (median dose 0.5 mg/kg/day in prednisone equivalents). Because of the nature of the adverse reactions seen with the concurrent use of etanercept and anakinra therapy, similar toxicities may also result from the concurrent use of anakinra and other TNF blockers. The most commonly reported infections were upper respiratory tract infection and pharyngitis, and the most commonly reported serious infection was pneumonia. In addition, a greater proportion of patients in Remicade groups demonstrated sustained response and sustained remission than in the placebo groups (Table 5).Of patients on corticosteroids at baseline, greater proportions of adult patients in the Remicade treatment groups were in clinical remission and able to discontinue corticosteroids at Week 30 compared with the patients in the placebo treatment groups (22% in Remicade treatment groups vs. 10% in placebo group in Study UC I; 23% in Remicade treatment groups vs. 3% in placebo group in Study UC II).
Our September issue is available online: Rhodes J, Bainton D, Beck P, Campbell H. Controlled trial of azathioprine in Crohn’s disease. Stratified by PASI response at Week 10 and investigational site, patients in the active treatment groups were re-randomized to either a scheduled or as needed maintenance (PRN) therapy, beginning on Week 14.The groups that received a maintenance dose every 8 weeks appear to have a greater percentage of patients maintaining a PASI 75 through Week 50 as compared to patients who received the as-needed or PRN doses, and the best response was maintained with the 5 mg/kg every 8-week dose.